Teva draws up mid-stage study plans for vitiligo asset on Phase Ib success

Phase 2positiveTEV-408Positive

AI Analysis

Summary

Teva announced positive Phase Ib results for TEV-408 in vitiligo and plans to initiate a Phase IIb study in Q4 2026. The advancement demonstrates clinical progress for the vitiligo asset.

Clinical Trial Data

Phase

Phase Ib/IIb

Primary Endpoint

Met

Outcome Details

Phase Ib trial of TEV-408 in vitiligo showed positive results

Importance:6/10

Sentiment:

0.70

vitiligodermatologyPhase Ib successPhase IIb progression

Related Companies

$TEVA

Read the original article

Published by Clinical Trials Arena on July 8, 2026 9:57 AM

Read Original